
Harness Therapeutics nominates drug candidate for Huntington’s
Harness Therapeutics has announced the nomination of HRN001 as its lead drug candidate for Huntington’s disease (HD). The company has also formed a clinical advisory board to support the programme’s advancement towards clinical evaluation. Despite significant advances in understanding HD disease biology, there are currently… Read More
